
Organ Regeneration is Now Reality

Hyper-Personalized Skin Regeneration Platform



ABOUT US

ROKIT Healthcare takes a holistic approach to regenerative therapy, emerging disruptive bioprinting technologies with an autologous therapeutic solution. We are committed to providing the safest and effective autologous organ regeneration platform with the promise of a new era of regenerative therapies.



3 MAIN BUSINESS AREAS

ORGAN REGENERATION

The Organ Regeneration division applies the latest science in Al-assisted 4D bioprinting and autologous patient's solution to personalized regenerative medicine.

GENOMICS

The Genomics division translates single-cell RNA sequencing to offer disease prevention informed by the patient's genetic data.

ANTI-AGING


The Anti-Aging division focuses on the day-to-day care of the body through diet supplements and cosmeceutical products.

Dr.INVIVO SYSTEM



*AI-Assisted Software


AiD Regen is an artificial intelligence (AI)-based wound measurement software for 3D model generation. The creation of a 3D model starts from a set of wound images, where the software scans the affected wound areas perfectly matching the wound dimensions.



*4D Bioprinting Technology

Dr.INVIVO 4D2D is a 4D bioprinter developed to print a customized skin regenerative patch for wound healing.





* Sterilized Single-Use Kit

Dr.INVIVO AI Regen KIT is a single-use disposable kit per patient, composed of sterile accessories and printing supplies that are used in conjunction with Dr.INVIVO 4D2D.









HYPER-PERSONALIZED SKIN REGENERATION PLATFORM

We provide an effective, customized regenerative therapy for treating deep, non-healing chronic wounds using an autologous solution with our 4D disruptive bioprinting technology. As a leading innovative healthcare company, ROKIT has brought a new paradigm in regenerative therapy, enhancing both efficacy and safety as proven through global clinical studies.



THE NEW ERA OF REGENERATIVE THERAPY



CLINICAL STUDY – INDIA

The results of the study proved the efficacy of our innovative treatment, the proportion of subjects achieving complete wound closure at week 12 in the test group was 100% and 50% in the control group at week 12 (P<0.0001, **).



Kesavan, R., et al. (2021). The International Journal of Lower Extremity Wounds, 15347346211045625. The Computational Foundation of Computational Foundation (Computational Foundational Foundational

